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Steroid-resistant nephrotic syndrome (SRNS) causes 15% of chronic kidney disease cases. A mutation in 1 of over 40 
monogenic genes can be detected in approximately 30% of individuals with SRNS whose symptoms manifest before 25 
years of age. However, in many patients, the genetic etiology remains unknown. Here, we have performed whole exome 
sequencing to identify recessive causes of SRNS. In 7 families with SRNS and facultative ichthyosis, adrenal insufficiency, 
immunodeficiency, and neurological defects, we identified 9 different recessive mutations in SGPL1, which encodes 
sphingosine-1-phosphate (S1P) lyase. All mutations resulted in reduced or absent SGPL1 protein and/or enzyme activity. 
Overexpression of cDNA representing SGPL1 mutations resulted in subcellular mislocalization of SGPL1. Furthermore, 
expression of WT human SGPL1 rescued growth of SGPL1-deficient dpl1Δ yeast strains, whereas expression of disease-
associated variants did not. Immunofluorescence revealed SGPL1 expression in mouse podocytes and mesangial cells. 
Knockdown of Sgpl1 in rat mesangial cells inhibited cell migration, which was partially rescued by VPC23109, an S1P receptor 
antagonist. In Drosophila, Sply mutants, which lack SGPL1, displayed a phenotype reminiscent of nephrotic syndrome in 
nephrocytes. WT Sply, but not the disease-associated variants, rescued this phenotype. Together, these results indicate that 
SGPL1 mutations cause a syndromic form of SRNS.
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and Figure 1, B–E). A homozygous frameshift mutation of SGPL1 
(p.Ser3Lysfs*11) (Table 2 and Figure 1, B–E) was identified in 
affected individuals from family A5444, showing a phenotype of 
SRNS and cortisol deficiency. In family B46/B56, in whom 3 sib-
lings had congenital nephrotic syndrome (NS) and severe extra-
renal involvement combined with lymphopenia (Table 2 and Sup-
plemental Figure 1), WES detected another homozygous missense 
mutation of SGPL1 (p.Ser346Ile) (Table 2 and Figure 1, B–E) and 
in another individual with a related disease phenotype, B1245, a 
homozygous missense mutation, p.Tyr416Cys (Table 2 and Figure 
1, B–E), with both mutations evolutionarily conserved to S. cere-
visiae. In an individual MC with mononeuritis multiplex, SRNS, 
lymphopenia, and progressive contractures of extremities, WES 
identified compound heterozygous mutations in SGPL1 (Table 2 
and Figure 1, B–E). Both mutations are missense and affect highly 
conserved amino acid residues.
Patients from the nonconsanguineous family NCR61 (Table 1 
and Figure 1, B–E) were found to be compound heterozygous for 
a frameshift mutation (p.Arg278Glyfs*17) and a missense muta-
tion (p.Glu132Gly) not predicted to be deleterious by the Poly-
Phen (http://genetics.bwh.harvard.edu/pph2/) and SIFT (http://
sift.jcvi.org/) prediction tools, but predicted to induce skipping of 
exon 5 due to the introduction of additional exon splicing silencer 
elements (EX-SKIP, http://ex-skip.img.cas.cz) (8). Fibroblasts of 
patient NCR61-1 had almost no SGPL1 protein detectable by West-
ern blot at the predicted size (Supplemental Figure 4A). There-
fore, we hypothesized that the deleterious effect of c.395A>G was 
indeed related to the predicted RNA splicing defect and not to the 
p.Glu132Gly amino acid substitution. Amplification of the patient 
cDNA between exons 4 and 8 by PCR revealed a light band at the 
expected size and an intense smaller band with a size correspond-
ing to loss of exon 5 (Supplemental Figure 4B). Sequencing of the 
PCR products confirmed the absence of exon 5 for the abundant 
smaller fragment and showed that the normal size fragment cor-
responded to the frameshift allele p.Arg278Glyfs*17. Skipping of 
exon 5 leads to a frameshift at amino acid position 88 and a stop 
codon 24 amino acids downstream (p. Ile88Thrfs*25).
By high-throughput exon sequencing (5, 9) in a worldwide 
cohort of approximately 800 additional families with NS, we 
did not detect any additional families with biallelic mutations of 
SGPL1. In all 7 families with SGPL1 mutations (Tables 1 and 2 and 
Figure 1, B–K), direct inspection of sequence alignments did not 
yield a mutation in any of the 40 known SRNS genes. Most muta-
tions identified in this study were absent from more than 60,000 
control individuals in the ExAC server (http://exac.broadinsti-
tute.org/) (Tables 1 and 2). Two missense mutations (c.665G>A; 
p.Arg222Gln and c.1247A>G; p.Tyr416Cys) are reported in the 
ExAC server, but their allele frequencies are extremely rare and 
they never occur in the homozygous state (Tables 1 and 2). All 
mutations segregated with the disease phenotype (Supplemental 
Figures 1 and 2). We thereby identified recessive SGPL1 mutations 
as a cause of syndromic SRNS with ichthyosis/acanthocystosis, 
adrenal insufficiency, immunodeficiency, or neurologic involve-
ment. We introduced the term NPHS14 for this syndromic SRNS 
caused by mutations of SGPL1.
In the majority of cases, NS, manifested as congenital NS or 
in the first year of life, showed no response to steroid therapy and 
Introduction
Steroid-resistant nephrotic syndrome (SRNS), when also resistant 
to other immunosuppressive agents, leads to chronic kidney dis-
ease (CKD) within a few years of onset, requiring renal replace-
ment therapy for survival. It causes 15% of all end-stage kidney 
disease that manifests by 25 years of age (1). Histologically, SRNS 
manifests mostly as focal segmental glomerulosclerosis (FSGS) (2).
The first insights into the pathogenesis of SRNS were gained 
by the discovery of monogenic causes of SRNS, revealing that the 
encoded proteins are essential for the function of the renal glo-
merular cells called podocytes (3, 4). We recently demonstrated 
in a worldwide cohort of 1,783 families that a monogenic cause of 
SRNS can be detected in 1 of 27 genes in approximately 30% of 
SRNS cases manifesting before age 25 years (5). Currently, more 
than 40 monogenic forms of SRNS have been identified (6).
Interestingly, syndromic forms of SRNS have been increasing-
ly characterized and display variable involvement of other organs 
besides the kidney, in most of the cases the central nervous system, 
but also the genital tract, eye, muscle, bone, and the immune sys-
tem. To date, mutations have been identified in transcription factors 
and nuclear proteins (WT1, LMX1B, SMARCAL1, NXF5, NUP93, 
NUP205, and XPO5), lysosomal proteins (SCARB2), basement 
membrane proteins (LAMB2), and proteins involved in COQ 10 
biosynthesis (COQ2, COQ6, PDSS2, and ADCK4) (6). Because 
genetic mapping data indicated a multitude of potential additional 
loci for SRNS, we here performed whole exome sequencing (WES) 
to identify additional monogenic SRNS genes and identified 9 
different mutations in sphingosine-1-phosphate lyase (SGPL1) in 
7 families as causing a previously unrecognized syndromic SRNS 
with a combination of ichthyosis/acanthosis, adrenal insufficiency, 
immunodeficiency, and/or neuronal dysfunction. We character-
ized mechanisms of molecular loss of function for the mutations 
detected and implicated sphingosine-1-phosphate (S1P) metabo-
lism in the pathogenesis of SRNS. The syndromic features resulting 
from SGPL1 mutations indicate the pivotal role of S1P metabolism 
in multiple tissues including kidney.
Results
SGPL1 mutations cause nephrotic syndrome, ichthyosis, faculta-
tive adrenal insufficiency, immunodeficiency, and neurologic defects 
in humans. Using WES in 7 families with a disease phenotype of 
SRNS, with adrenal insufficiency, ichthyosis-like acanthosis, 
immunodeficiency, or neurologic abnormalities (Table 1, Table 2, 
and Supplemental Figures 1–3; supplemental material available 
online with this article; https://doi.org/10.1172/JCI89626DS1), 
we identified recessive mutations in SGPL1 (Figure 1, A–E). Homo-
zygosity mapping (HM) in a Pakistani family (A280) (Supplemen-
tal Figure 1) with 3 siblings yielded a nonparametric lod score peak 
on chromosome 10, which did not coincide with any of the known 
recessive SRNS loci (Figure 1A) (7). Using WES, we detected a 
homozygous missense mutation (p.Arg222Gln) in a highly con-
served (Caenorhabditis elegans) amino acid residue encoded by 
SGPL1 (Table 1 and Figure 1, B–E). Notably, affected individuals 
from another consanguineous family (EB) showed a homozy-
gous missense mutation involving the same amino acid residue 
(p. Arg222Trp), but presented with a more severe phenotype, 
with neonatal onset and profound immunodeficiency (Table 1  
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rapidly progressed to end-stage renal disease (ESRD). Histologi-
cally, FSGS was the main finding, but diffuse mesangial sclerosis 
(DMS) was found in cases with congenital NS (Tables 1 and 2 and 
Supplemental Figure 3). Extrarenal manifestations included ich-
thyosis and primary adrenal insufficiency, present in almost all 
cases except in those patients deceased at very early ages. About 
half of the affected individuals had a severe immunodeficiency. 
Patients presented with lymphopenia and multiple bacterial infec-
tions. A more detailed immunological work-up performed in 
patient EB-1 revealed severe lymphopenia with markedly reduced 
CD4 and CD8 T lymphocytes as well as B lymphocytes. In vitro 
cytokine generation upon stimulation was also deficient (Supple-
mental Table 3). Neurological deficits were also present in half of 
the patients and included sensorineural deafness, microcephaly 
(Supplemental Figure 3), corpus callosum hypoplasia in 1 case, 
peripheral nerve paralysis of the median and ulnar nerves, and 
ptosis of the left eye (Tables 1 and 2 and Figure 1, F–I). In a few 
cases, dysmorphic features and bone defects were also present. 
Two families had a history of fetal demise and hydrops fetalis.
SGPL1 encodes S1P lyase, an intracellular enzyme responsible 
for the final step in sphingolipid breakdown, converting its main sub-
strate S1P into ethanolamine phosphate and hexadecenal. S1P is a 
bioactive sphingolipid that acts extracellularly by binding to protein-
coupled receptors of the lysophospholipid receptor family and intra-
cellularly through S1P receptor–independent (S1PR-independent) 
mechanisms. Through receptor activation, S1P mediates autocrine 
and paracrine signals, controlling cell migration and proliferation as 
well as lamellipodia dynamics (10). An Sgpl1-deficient mouse model 
exhibits glomerular proteinuria, a skin phenotype of acanthosis with 
orthokeratotic hyperkeratosis and platelet activation (11).
Sgpl1 localizes to the endoplasmic reticulum of renal glomerular 
cells. All of the 40 monogenic genes that, when mutated, cause 
SRNS are highly expressed in podocytes. We therefore examined 
cell-type–specific and subcellular localization of SGPL1 in mouse 
kidney. To assess the specificity of an anti-SGPL1 antibody used 
in immunofluorescence, we first stained kidney sections of Sgpl1–/– 
and Sgpl1+/+ mice (Figure 2, A and B). Most of the SGPL1 signal 
observed in kidneys of Sgpl1+/+ mice was absent from kidneys of 
Sgpl1–/– mice (Figure 2A), demonstrating specificity of the signal. 
To determine cellular localization of SGPL1, immunofluorescence 
was performed using various cell- and organelle-specific mark-
ers (Figure 2, C–F). SGPL1 localized to podocytes, whose nuclei 
were marked with WT1 (Figure 2C). As shown by the colocaliza-
tion of SGPL1 with the ER marker BiP, it localized to ER in podo-
cytes, although this colocalization was more obvious in proximal 
tubules (Figure 2C). In addition, SGPL1 appeared to be present in 
other renal glomerular cell types, for example, in mesangial cells 
stained with α–smooth muscle actin (Figure 2E) and endothelial 
cells stained with CD31 (Figure 2F).
In silico modeling of SGPL1 missense mutations. To predict 
potential structural changes in SGPL1 protein that might arise 
from the mutations (p.Arg222Gln and p.Ser346Ile) detected in 
patients with NPHS type 14 Tables 1 and 2), we performed in silico 
analyses (Figure 2, G and H). SGPL1 forms a symmetric homodi-
mer. Two subunits form a tightly intertwined dimer with both 
chains contributing to the catalytic cavity defined by the covalent-
ly bound cofactor pyridoxal phosphate (PLP) (Figure 2, G and H). 
Arg222 is located at the symmetric dimer interface and forms 2 
important hydrogen bonds with the carbonyl backbone moieties 
of Tyr250 and Ser249, contributing to the binding affinity of the 
homodimer. The p.Arg222Gln mutation leads to a loss of these 2 
hydrogen bonds in both chains (Figure 2G), which is reflected in 
the delta affinity being predicted as unfavorable by about 10 kcal/
mol. In addition, the mutation seems to be destabilizing the pro-
tein, since Arg222 also forms hydrogen bonds with adjacent resi-
dues in its own symmetric dimer chain. Ser346 is not at the dimer 
interface, but buried within each chain (Figure 2H). Its hydroxyl 
group is involved in 2 hydrogen bonds, accepting one from Tyr221 
and donating one onto His313 (Figure 2H). The p.Ser346Ile muta-
tion is predicted to be considerably disfavored because it not only 
breaks this hydrogen-bond network, but because isoleucine is 
also much bulkier than serine, leading to steric clashes with its 
surrounding residues (Figure 2H). Hence the delta stability is pre-
dicted to be +130 kcal/mol.
Mutations alter subcellular localization of SGPL1. Because in 
silico analysis predicted that the p.Arg222Gln mutation may affect 
the interface of the SGPL1 homodimer, we examined this hypoth-
esis by coimmunoprecipitation. We transfected HEK293T cells 
with plasmids with 2 alternative tags (Myc and FLAG). Compared 
with WT SGPL1, p.Arg222Gln and p.Ser346Ile mutant proteins 
exhibited reduced expression levels, whereas p.Glu132Gly had a 
similar expression level upon overexpression (Figure 2I and Sup-
plemental Figure 5). Neither missense (p.Glu132Gly, p.Arg222Gln, 
and p.Ser346Ile) nor truncating (p.Arg278Glyfs*17) mutations 
abrogated dimer formation (Figure 2I and Supplemental Figure 
5). However, when compared with overexpression of the SGPL1 
WT construct, overexpression of p.Arg222Gln, p.Ser346Ile, and 
p.Arg278Glyfs*17 SGPL1 proteins in HEK293T cells led to abnor-
mal cytoplasmic aggregates (Figure 2J). Aggregation of SGPL1 
mutant proteins was confirmed upon overexpression in human 
podocytes (Supplemental Figure 6).
Figure 1. HM and WES reveal SGPL1 mutations as causing SRNS with 
ichthyosis and facultative adrenal insufficiency or neurologic defects 
(NPHS type 14). (A) Nonparametric lod scores across the human genome 
in 3 siblings of consanguineous family A280 with SRNS, acanthosis, and 
ichtyosis with facultative adrenal insufficiency. The x axis shows single-
nucleotide polymorphism positions on human chromosomes concatenated 
from p-ter (left) to q-ter (right). Genetic distance is given in cM. The SGPL1 
locus (arrowhead) is positioned within the maximum nonparametric 
lod peak on chromosome 10. (B) Exon structure of human SGPL1 cDNA. 
SGPL1 contains 15 exons. Positions of start codon (ATG) and of stop 
codon (TGA) are indicated. (C) Domain structure of SGPL1. The extent of 
the PLP-dependent transferase domain is shown. (D) Five homozygous 
(HOM) and 4 compound-heterozygous SGPL1 mutations (het) detected in 7 
families with NPHS type 14. Family numbers (underlined), mutations, and 
predicted translational changes are indicated (see also Tables 1 and 2). (E) 
Evolutionary conservation of altered amino acid residues of SGPL1. Note 
that c.395A>G also resulted in p.Ile88Thrfs*25 through exon 5 skipping. 
(F) Ptosis in individual A280-22. (G) Skin image from individual A280-22 
showing brownish black desquamation on sebostatic skin with multiple 
radial papules with a blueish/black erythema and central calcinosis. (H and 
I) Median (H) and ulnar nerve (I) paralysis in individual A280-22. (J) H&E-
stained epidermal section from individual A280-22 showing acanthosis/
orthokeratotic hyperkeratosis (black arrowhead) and calcinosis (white 
arrowhead). (K) Renal histology (silver staining) of individual A280-22, 
showing FSGS. Scale bars: 100 μm.
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our finding that the c.395A>G allele most likely conveys loss of 
function through its splice defect (Supplemental Figure 4B). The 
results were also reproduced on plates containing C17 and C18 
dihydrosphingosine (DHS).
To further investigate functional consequences of SGPL1 
mutants, we carried out a synthetic lethality assay in yeast (Figure 
2O and Supplemental Figure 7B) using an RH4863 strain in which 
DPL1 and LCB3 were deleted, rendering the strain synthetically 
lethal. Viability of the strain was maintained by expressing LCB3 
from a URA3 plasmid. We tested functionality of SGPL1 and cor-
responding mutants expressed in RH4863 by forcing them to lose 
LCB3-coding URA3 plasmid on plates containing 5-fluoroorotic 
acid (5-FOA), which selects against URA3-expressing cells. Sur-
vival on 5-FOA plates indicates that cells have regained the ability 
to degrade long-chain bases and thus compensate for the loss of 
LCB3. In agreement with the PHS toxicity test, synthetic lethality 
assay demonstrated functional integrity of WT and p.Glu132Gly 
mutant SGPL1 proteins, but not p.Arg222Gln, p.Ser346Ile, 
p.Tyr416Cys, p.Arg278Glyfs*17, and p.Ser3Lysfs*11 (Figure 2O 
and Supplemental Figure 7B).
SGPL1 mutations alter ceramide composition of patient fibro-
blast-conditioned medium. S1P participates in regulating multiple 
cellular processes, and its intracellular levels are tightly regulated. 
Since SGPL1 controls the only exit point for sphingolipid catabo-
lism, inactivation of the enzyme can result in accumulation of 
various bioactive sphingolipid intermediates, including phosphor-
ylated and nonphosphorylated sphingoid bases and ceramides.
Conditioned medium from patient fibroblast cultures 
showed significantly elevated C22:0, C24:0, and C24:1 cerami-
des compared with control fibroblast-conditioned medium, 
whereas S1P levels were below the limits of detection (Supple-
mental Figure 8). These very long chain ceramides are produced 
by ceramide synthase 2 (12).
Sgpl1–/– mice exhibit podocyte foot process effacement. Sgpl1–/– 
mice exhibit glomerular proteinuria, a skin phenotype of acan-
thosis with orthokeratotic hyperkeratosis, platelet activation, and 
immunodeficiency (11). In order to determine the renal histology 
of Sgpl1–/– mice, we performed transmission electron microscopy 
(TEM) of kidneys harvested from Sgpl1+/+ and Sgpl1–/– mice to 
directly examine glomerular structures upon loss of Sgpl1. Sgpl1–/– 
kidneys exhibited complete foot process effacement and absence 
of slit diaphragms (Supplemental Figure 9). In addition, Sgpl1–/– 
mice exhibited hypoalbuminemia (serum albumin KO 2.2 ± 0.6 
g/dl vs. WT or heterozygote [HET] 3.7 ± 0.4 g/dl, n = 4 KO and 
n = 6 WT or HET) and an elevated urinary albumin/creatinine 
ratio (ACR) (KO 1176.4 ± 932.8 vs. WT or HET 103.5 ± 94.2, n = 3 
KO, n = 5 WT or HET, P value, no significant difference).
However, when we examined apoptosis in response to S1P in 
cultured podocytes, we did not observe an effect in a dose range 
expected to be present in SGPL1-induced pathology (Supplemen-
tal Figure 10). Likewise, we did not observe any effect of SGPL1 
knockdown on podocyte migration rate, a pathogenic effect that 
has previously been demonstrated in many monogenic forms of 
SRNS (Supplemental Figure 11) (13).
Decreased mesangial cell migration rate upon SGPL1 knockdown 
is reversed by an S1PR inhibitor. Because we did not observe any 
cellular pathologic effect in cultured podocytes regarding apop-
Mutations in SGPL1 result in decreased expression and reduced lyase 
activity. To assess whether mutations detected in individuals with 
NPHS type 14 altered SGPL1 enzyme activity, we measured SGPL1 
and enzyme activity levels in HEK293T cells transiently express-
ing either WT or mutant SGPL1 (Figure 2K). We found that over-
expression of the p.Arg222Gln, p.Ser346Ile, and p.Arg278Glyfs*17 
mutant alleles resulted in strongly reduced enzyme activity levels, 
whereas the p.Glu132Gly mutant (c.395A>G) did not, consistent 
with our finding that c.395A>G leads to skipping of exon 5 and 
protein truncation (p.Ile88Thrfs*25) (Supplemental Figure 4). 
We also found that protein expression levels and corresponding 
SGPL1 enzyme activity levels in patient dermal fibroblasts (Fig-
ure 2L) exhibited reduced SGPL1 enzyme activity for individuals 
B46 (p.Ser346Ile), B56 (p.Ser346Ile), NCR 61-1 (p.R278fs*17 and 
p.Ile88Thrfs*25), and A280-21 (p.Arg222Gln) compared with 
controls (Figure 2L). In addition, there was reduced expression of 
SGPL1 protein when examined by immunofluorescence microsco-
py in patient fibroblasts (Figure 2M). Taken together, these results 
suggest that the primary impact of the patient’s mutations is on 
SGPL1 expression level and protein stability.
SGPL1 mutations fail to rescue growth in DPL1-deficient yeast. 
Functionality of human WT and mutant SGPL1 proteins were 
tested in an in vivo yeast complementation assay by measuring 
their ability to complement the deletion of the SGPL1 yeast ortho-
log DPL1 (dpl1Δ) on medium containing phytosphingosine (PHS) 
(Figure 2N and Supplemental Figure 7A). Inability to degrade tox-
ic long-chain bases led to decreased viability and slowed growth. 
Human WT and p.Glu132Gly mutant SGPL1 were found to be 
able to partially restore dpl1Δ, while p.Arg222Gln, p.Ser346Ile, 
and p.Tyr416Cys as well as frameshift mutants p.Arg278Glyfs*17 
and p.Ser3Lysfs*11 showed no improved growth compared with 
dpl1Δ (Figure 2N and Supplemental Figure 7A), consistent with 
Figure 2. Biological and biochemical consequences of recessive SGPL1 
mutations. (A–F) Kidney sections of Sgpl1–/– mice (A) and Sgpl1+/+ mice (B) 
were stained with anti-SGPL1 (red) and WT1 antibodies (green). (B–F) Coim-
munofluorescence of SGPL1 with marker proteins (green) in Sgpl1+/+ kidney: 
podocyte (B, WT1), ER (C, BiP), podocyte foot processes (D, synaptopodin), 
mesangial cells (E, α–smooth muscle actin), and endothelial cells (F, CD31). 
Scale bars: 25 μm. (G and H) Structural modeling of SGPL1 mutations. The 
2 monomers of the SGPL1 homodimer are shown in the drawing in blue 
and orange, respectively. (G) p.Arg222Gln; (H) p.Ser346Ile. (I) Coimmuno-
precipitation to assess dimerization of WT vs. mutant SGPL1 proteins (see 
also Supplemental Figure 5). Coimmunoprecipitation is representative of 3 
experiments. (J) Mislocalization of variant SGPL1 proteins upon overexpres-
sion in HEK293T cells. BiP (red), or Golgi marker GOLGB1 (red), and anti-Myc 
antibody (green). Scale bars: 10 μm. (K) SGPL1 enzyme activity levels in 
transformed HEK293T cells. HEK293T cells expressing a GFP indicate 
endogenous SGPL1 activity levels (a vs. b and a vs. d, P < 0.0025; c vs. d,  
P = 0.013; a vs. c, no significant difference). (L) SGPL1 protein expression 
and enzyme activity levels in fibroblasts from 2 control individuals (Ctrl 
1 and 2), normal human foreskin fibroblasts (Fk), and 4 individuals with 
SGPL1 mutations. (a vs. b, P < 0.0001.) Results are from the averages of 
triplicates in K and L. (M) Immunofluorescence of SGPL1 in fibroblasts. BiP 
(green), Golgi marker GM130 (blue), and anti-SGPL1 antibody (red). Scale 
bars: 25 μm. (N) PHS toxicity test. Ability to complement dpl1Δ deletion on 
medium containing PHS was tested for human SGPL1 WT and mutants. 
(O) Synthetic lethality test. Human WT and p.Glu132Gly SGPL1 expressing 
RH4863 survived on 5-FOA plates. However, p.Arg222Gln and p.Ser346Ile 
mutants did not allow for survival of DPL1 (SGPL1) deficient strains.
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S1P has previously been implicated in the regulation of RHO-
like small GTPases (RHOA/RAC1/CDC42), and disruption of 
RAC1 signaling was previously implicated in the pathogenesis of 
SRNS (13–15). We therefore tested whether knockdown of SGPL1 
would affect activation of the RHO-like small GTPases. When 
Sgpl1 was silenced by siRNA in RMCs, we observed a decrease in 
active GTP forms of CDC42 and RAC1 (Figure 3C), whereas active 
RHOA (Figure 3D) was unchanged.
To test for specificity of the migration defect observed upon 
Sgpl1 knockdown, we employed S1PR antagonists. Among 5 S1PR 
(S1PR1-5), S1PR1, S1PR2, and S1PR3 are expressed in kidney (16). 
Therefore, we chose VPC23109, which preferentially acts on S1PR1 
and S1PR3, and JTE013, which is an antagonist for S1PR2. Inter-
estingly, VPC23109 partially rescued the decreased migration 
conferred by Sgpl1 knockdown in RMCs, whereas JTE013 failed to 
tosis or cell migration, because SGPL1 was present in mesangial 
cells (Figure 2E), and because Sgpl1–/– mice exhibited reduced glo-
merular mesangial cell numbers (11), we examined pathogenic 
effects of siRNA knockdown of Sgpl1 in mesangial cells (Figure 3).
To test whether SGPL1 or S1P is involved in cell survival or 
proliferation, we investigated the effect of silencing SGPL1 on 
cell apoptosis and proliferation in rat mesangial cells (RMCs). 
Knockdown of Sgpl1 did not affect apoptosis or proliferation in 
RMCs (Supplemental Figure 12). We then examined the effect of 
Sgpl1 knockdown on migration of RMCs and found that migration 
of RMCs was reduced (Figure 3A) upon knockdown of Sgpl1 by 
transfection with either of 2 siRNAs (Supplemental Figure 12). 
In addition, we confirmed this effect by showing that cell migra-
tion was significantly reduced in fibroblasts from individuals with 
SGPL1 mutations (Figure 3B).
Figure 3. Effect of Sgpl1 knockdown on RHO GTPase activity in RMCs and patient fibroblasts. (A) Effect of SGPL1 knockdown on rat RMCs using the 
xCELLigence system. RMC transfected with 2 different SGPL1 siRNAs exhibited decreased serum-induced migration rate (blue and red lines) compared 
with scrambled siRNA control (black line). (B) Diminished cell migration rate in patients with SGPL1 mutations. Using the xCELLigence system, fibroblasts 
from individuals with SGPL1 mutations (blue, red, and orange lines) showed decreased migration rate compared with control (black solid line). (C) Active 
GTP-bound RAC1 and CDC42 precipitated from RMCs transfected with scrambled (Scr) or SGPL1 siRNA using a GST-PAK1 (CRIB) pulldown assay. Compared 
with control cells, RMCs transfected with SGPL1 siRNA exhibited a significant decrease in relative CDC42 and RAC1 activity. The efficiency of knockdown 
by siRNA was confirmed by immunoblotting with an anti-SGPL1 antibody (second to lowest panel). (D) Active GTP-bound RHOA precipitated from RMCs 
using a GST-rhotekin (RBD) pulldown assay. RMCs transfected with scrambled control siRNA versus SGPL1 siRNA exhibited no significant differences in 
relative RHOA activity. C and D represent 3 experiments each. (E) Effect of S1PR antagonists on RMC migration rate. SGPL1 knockdown caused decreased 
migration rate (red line) (Supplemental Figure 3B), which was partially rescued by VPC23109 (green line), but not by JTE013 (orange line). VPC23109 is an 
antagonist that selectively inhibits S1PR1 and S1PR3, whereas JTE013 is an antagonist for S1PR2. Each cell index value corresponds to the average of more 
than triplicates and SD is in only 1 direction for clarity in A, B, and E.
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Reexpression of Sply WT and p.Glu119Gly transgenes res-
cued Sply mutant viability defect and nephrocyte dysfunction, 
which was not the case for p.Arg210Gln and p.Ser335Ile muta-
tions (Figure 4 and Figure 5A). Regarding the neutral lipid content 
of nephrocytes, we observed a rescue of the Sply phenotype with 
Sply WT and p.Glu119Gly transgenes, but not with p.Arg210Gln or 
p.Ser335Ile (Figure 5B).
In whole third instar larvae, the phenotype of C16 sphingosine 
and C16 ceramide accumulation present in Sply null hemizygous 
flies was rescued with equal efficiency by Sply WT and p.Glu119G 
transgenes (Figure 5C). However, p.Ser335Ile mutant failed to res-
cue (Figure 5C). p.Arg210Gln mutant partially rescued the Sply 
null phenotype, but with significantly less efficiency than Sply 
WT (Figure 5C). This suggests that p.Arg210Gln and p.Ser335Ile, 
but not p.Glu119Gly, mutations affect the Sply enzymatic activity 
and result in the accumulation of upstream sphingolipids, sphin-
gosines, and ceramides. Similar results were observed when ana-
lyzing fly sphingadienes, although complementation results for 
the mutants p.Arg210Gln and p.Ser335Ile did not reach a statisti-
cally significant difference from control (Supplemental Figure 14). 
We conclude that SGPL1 missense mutations p.Arg222Gln and 
p.Ser346Ile are pathogenic, impair sphingolipid metabolism, and 
induce nephrocyte defects reminiscent of those found in human 
podocytopathies. Consistent with our data on the splicing defects 
(Supplemental Figure 4B) induced by p.Glu132Gly mutation, we 
found that the corresponding amino acid change did not induce 
any defect in Drosophila.
Discussion
In this study, we identified recessive SGPL1 mutations as a cause 
of syndromic SRNS. The disease phenotype entailed SRNS with 
facultative ichthyosis, adrenal insufficiency, neurologic involve-
ment, and immunodeficiency. We show that SGPL1 mutations 
are loss-of-function mutations that lead to reduced protein lev-
els and enzyme activity and impaired degradation of long-chain 
sphingoid bases. In Drosophila, the missense mutations led to 
decreased viability and nephrocyte defects that are reminiscent 
of podocyte changes in human NS. WT Sply complemented Sply 
phenotype and sphingolipid profiles, whereas Sply harboring 
mutations did not complement.
SGPL1 is ubiquitously expressed in tissues and is an essential 
enzyme of the sphingolipid catabolic pathway. It is thus consid-
ered a main regulator of S1P levels and other sphingoid bases. Loss 
of Sgpl1 in mouse models phenocopies the human disease. In fact, 
Sgpl1–/– mice fail to thrive and die soon after weaning, showing 
defects in the immune system, the urinary system, vasculature, 
and bone as well as altered lipid metabolism (11, 23–25). However, 
adrenal insufficiency has not been described in Sgpl1–/– mice, but 
to our knowledge, adrenal function was not assessed in these ani-
mals. In the immune system, changes in local S1P concentration 
and gradient between tissues (low S1P) and efferent lymph and 
blood (high S1P) affect T cell egress from lymphoid organs (26, 
27), resulting in reduced levels of circulating lymphocytes with 
overrepresentation of T cells with a memory phenotype over naive 
T cells (27), as observed in the SGPL1 mutant patient in which a 
complete immunological work-up has been performed. Interest-
ingly, partial deficiency of Sgpl1 in inducible knockout models led 
rescue the migration defect, suggesting that the S1P effect on RMC 
migration rate is mediated through S1PR1 and/or S1PR3 (Figure 3E).
SGPL1 is required for Drosophila nephrocyte function. Sply is 
the SGPL1 ortholog of Drosophila, and a Sply null allele has pre-
viously been characterized and shown to decrease fly viability 
(17). Accordingly, Sply null hemizygous flies (Sply null/Df) had 
decreased viability (Figure 4A).
To assess whether Sply deficiency evoked a podocytopathy 
phenotype in flies, we assessed the structure and function of neph-
rocytes in Sply null hemizygous flies. Nephrocytes are thought to 
represent the Drosophila counterparts of podocytes. These cells 
display invaginations of plasma membrane that form analogous 
structures to podocyte foot processes and are connected by a slit 
diaphragm (18). This structure allows filtering of hemolymph and 
macromolecules that can then undergo endocytosis. We observed 
no major decrease of the slit diaphragm protein kirre (NEPH1 
ortholog) by immunofluorescence (Supplemental Figure 13); how-
ever, by TEM, we identified a reduction of foot process density 
(Figure 4C). To assess the impact of Sply on nephrocyte function, 
we analyzed the uptake of fluorescent-coupled albumin. Albumin 
is filtered and endocytosed in nephrocytes under normal condi-
tions, but not when there is disruption of foot processes (18, 19). 
Consistently, Sply null hemizygous flies had significantly reduced 
uptake of albumin as compared with control (Figure 5A).
Due to the known role of Sply on sphingolipid catabolic path-
way and its indirect implication in other lipid pathways, such as the 
regulation of sterol regulatory element-binding protein process-
ing in Drosophila (20), we also studied the effect of Sply KO on the 
lipid content of nephrocytes. Sply null hemizygous flies showed an 
almost complete absence of lipid droplets stained by Bodipy (Figure 
5B) or Nile red (data not shown), suggesting a reduction of neutral 
lipids. Using liquid chromatography–mass spectrometry (LC/MS), 
we also assessed the accumulation of sphingoid bases and cerami-
des in Sply null hemizygous flies. Drosophila has been shown to have 
C14 and C16 sphingosine (21) and C14 and C16 sphingadienes (22), 
a sphingoid base with an extra double bond compared with sphin-
gosine. Sphingolipid intermediates upstream of S1P, including long 
chain bases and ceramides, have been shown to accumulate when 
SGPL1 activity is inhibited, including in Sply mutant flies (17, 22). As 
expected, we observed a significant increase of C16 sphingosine, 
C14 sphingadiene, and C16 ceramide in Sply null hemizygous third 
instar larvae (Figure 5C and Supplemental Figure 14). Together, 
these data suggest that Sply null hemizygous flies have defects 
reminiscent of the podocyte disease found in humans with SGPL1 
mutations and display altered lipid metabolism due to the disrup-
tion of sphingolipid catabolic pathway.
Lack of rescue with mutant alleles in the Drosophila model. To 
assess the effect of SGPL1 missense mutations in vivo, we reex-
pressed the HA-tagged Sply carrying WT or the corresponding 
human mutations p.Glu119Gly, p.Arg210Gln, and p.Ser335Ile 
(equivalent to human mutants p.Glu132Gly, p.Arg222Gln, and 
p.Ser346Ile, respectively). We observed that under its endogenous 
promoter, HA-tagged Sply is expressed in nephrocytes (Figure 4B). 
Consistent with our previous results, the expression of mutants 
p.Arg210Gln and p.Ser335Ile was greatly reduced at the protein 
level compared with WT (Figure 4B), but without any significant 
difference at the mRNA level (Supplemental Figure 15).
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Figure 4. SGPL1 missense mutations fail to rescue the phenotype of 
the Drosophila SGPL1 ortholog (Sply) KO. Human SGPL1 mutations 
p.Glu132Gly, p.Arg222Gln, and p.Ser346Ile are equivalent to Drosophila 
Sply mutations p.Glu119Gly, p.Arg210Gln, and p.Ser335Ile. (A) Viability 
defects of Sply null hemizygous and Sply mutant flies. Viability was 
calculated as the percentage of Sply null hemizygous offspring of het-
erozygous parents. Values are normalized to the viable control Df(2R)
BSC433/Df(2R)247. More than 650 flies per genotype; 6 independent 
experiments. (B) Western blot of HA-tagged Sply in third instar larvae 
(top panel) and immunofluorescence of third instar garland nephro-
cytes stained for HA (purple) (bottom panel). Membrane and nuclei 
were labeled with HRP (green) and Hoechst (blue), respectively. Five or 
more larvae/genotype; 3 independent experiments. Scale bar: 10 μm. 
(C) Foot process density in Sply null hemizygous and Sply mutant third 
instar garland nephrocytes. TEM images and quantification. Six or 
more nephrocytes/genotype; 2 independent experiments. Scale bars: 
200 nm. Statistical analysis performed by Bonferroni’s test following 
ANOVA. ***P < 0.0005; *P < 0.05. All graphs show mean ± SEM. ns, 
not significant.
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Figure 5. Defects of vesicular transport and sphingosine metabolism in the SGPL1 drosophila ortholog (Sply) KO. (A) Albumin uptake in Sply null hemi-
zygous and Sply mutant third instar garland nephrocytes. Nephrocytes were incubated for 2.5 minutes with albumin-FITC (green), fixed and stained for 
the membrane marker HRP (red). Ten or more larvae/genotype; 3 independent experiments. Scale bar: 10 μm. (B) Lipid droplets in Sply null hemizygous 
and Sply mutant third instar garland nephrocytes, assessed by Bodipy staining. Six or more larvae/genotype; 2 independent experiments. Scale bar:  
10 μm. (C) Sphingoid bases accumulation in Sply null hemizygous and Sply mutant third instar larvae assessed by LC/MS. Note that p.Arg210Gln mutant 
rescues with less efficiency than Sply WT (p.Arg210Gln vs. Sply WT, P = 0.009 for sphingosines and P = 0.02 for ceramides, t test). n = 6 independent 
experiments. For Sply null, Sply WT, and p.E119G, 1 analysis was removed due to poor quality chromatography. Control corresponds to WT larvae. Statisti-
cal analysis performed by Dunnet’s (C) post-hoc tests following ANOVA or Dunn’s post-hoc test following Kruskal-Wallis (A). ***P < 0.0005; **P < 0.005; 
*P < 0.05. All graphs show mean ± SEM.
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argue against or in favor of a cell no-autonomous effect of SGPL1 
deficiency. However, in our study, cultured podocytes stimulated 
with S1P did not show increased apoptosis at the S1P expected 
disease level. Additionally, SGPL1 knockdown in podocytes also 
did not lead to a phenotype in cell migration or cell prolifera-
tion, although these results could be due to insufficient SGPL1 
decrease, since in neurons, a 70% reduction of SGPL1 using an 
RNA strategy is insufficient to induce accumulation of S1P (38). In 
Drosophila, there has still been no identification of a S1PR ortho-
logue. However, we cannot exclude the possibility of a Drosophila 
S1PR. Accordingly, the phenotype we observed in nephrocytes 
upon the constitutive Sply knockout cannot argue against or in 
favor of a cell-nonautonomous effect of SGPL1 deficiency.
However, in mesangial cells, SGPL1 knockdown induced a 
decrease of active RAC1 and CDC42 and a phenotype of decreased 
cell migration, which was partially mitigated by S1PR inhibition. 
Our findings in RMCs and Drosophila nephrocytes suggest that 
both cell types can be affected by SGPL1 deficiency, but it is not 
clear which cell type is primary in the pathogenesis. To address 
this, generation of transgenic mice with glomerular cell type– 
specific deletion of Sgpl1 is under way.
Methods
Study participants. We obtained clinical data, blood samples, and skin 
biopsies from SRNS patients from worldwide sources. The diagnosis 
of NS was made by nephrologists based on standardized clinical and 
histologic criteria (39). Renal biopsies were evaluated by pathologists. 
Additional, clinical data were obtained using a standardized question-
naire (http://www.renalgenes.org).
WES. In consanguineous families, we combined WES with HM, 
as established previously (40, 41). Genetic regions of homozygosity 
were plotted across the genome (Figure 1A) (42, 43). Exome capture 
was performed with the Agilent SureSelect V5 Enrichment Capture 
Kit. The enriched library was sequenced on an Illumina HiSeq 4000 
(100 bases paired end). Variant burden analysis was performed as 
previously described (44). Sequence reads were mapped against the 
human reference genome (NCBI build 37/hg19) using CLC Genomics 
Workbench (version 6.5.1) software (CLC bio). High-throughput exon 
resequencing was performed largely as described previously (9). For 
the nonconsanguineous family NCR61 and consanguineous family 
EB, exome sequencing was performed in 2 (NCR61-1 and NCR61-2) 
and 1 (EB-1) affected children. The enriched library was sequenced on 
an Illumina HiSeq 2500 (V4 chemistry, 2 × 125 bases). Variants were 
called as described (45).
RNA extraction, RT-PCR, and cDNA cloning. Human SGPL1 full-
length cDNA was obtained (clone MGC: 60255 IMAGE: 6150776) 
and subcloned into pRK5-N-Myc, pDEST69-N-FLAG, or BABE-
puro-gateway (Addgene plasmid no. 51070). Mutations were intro-
duced using the Quik Change II XL Site-Directed Mutagenesis Kit 
(Agilent Technologies).
SGPL1 enzymatic activity assay. SGPL1 activity in whole cell 
extracts of patient fibroblasts and HEK293T cells expressing WT and 
mutant SGPL1 cDNA constructs was measured by quantifying the 
amount of hexadecenal formed over time as described (46).
3D protein structure. The crystal structure of human SGPL1 (PDB 
code 4Q6R) was prepared using the protein preparation wizard in 
Schrödinger Maestro release 2015.1. (version 10.1). After protein prep-
to a less severe phenotype, with decreased lethality and in which 
prevailing manifestations involved kidney (massive proteinuria 
with FSGS), the immune system, platelets, and skin (28, 29). The 
variable organ involvement found in different SGPL1 mutated 
families may be related to levels of residual functional SGPL1 con-
veyed by different mutations. However, the intrafamilial variabil-
ity may be explained by the presence of other genetic factors that 
may influence the disease manifestations. For instance, variants 
or polymorphisms in genes involved in S1P metabolism and sig-
naling, such as SGPP1, SGPP2, SPHK1, SPHK2, SPNS2, or S1PR1-5, 
may contribute to intrafamilial variability.
The phenotypic spectrum of SGPL1 mutations is reminiscent 
of Schimke immunoosseous dysplasia (MIM 242900), which 
is caused by recessive mutations in SMARCAL1 encoding SWI/
SNF-related, matrix-associated, actin-dependent regulator of 
chromatin, subfamily A-like protein 1. Specifically, mutations 
in both SMARCAL1 and SGPL1 are associated with FSGS and T 
cell–related immunodeficiency. Whereas SMARCAL1 is involved 
in reannealing stably unwound DNA, SGPL1 has been implicated 
as a mediator of DNA damage response (DDR). Increased SGPL1 
expression and activity in DDR promotes apoptosis through a 
pathway involving p53 and caspase 2 (30). Therefore, defects in 
DDR may also contribute to the pathogenesis of SGPL1 deficiency. 
However, it should be noted that the T cell defects in patients with 
SMARCAL1 mutations are global and involve impairment of T cell 
proliferation, survival, and function. In contrast, SGPL1 deficiency 
in mice leads to lymphopenia as a result of trafficking defects, as 
shown by the sequestration of mature T cells in mutant mouse 
thymus, whereas T cell proliferation in thymus is unaffected (J.D. 
Saba and colleagues, unpublished observations).
Patient fibroblasts had significantly elevated C22:0, C24:0, 
and C24:1 ceramides compared with control fibroblast (Supple-
mental Figure 8). Interestingly, total serum ceramide levels and 
C24:0 and C16:0 lactyosylceramides were found to be high in 
children with CKD, which suggests they may play a causal role in 
the development of FSGS in our cohort (31). Total ceramide levels 
and the balance of different ceramide species can influence apop-
tosis and autophagy, thereby contributing to the pathophysiology 
of many diseases.
S1P is a bioactive lipid implicated in the regulation of cell sur-
vival, apoptosis, proliferation, and migration (32, 33). It can act in 
a paracrine and autocrine fashion by acting on G protein–coupled 
S1PRs that account for activation of signaling pathways such as 
Akt, mTOR, and RHO/RAC/CDC42 (34). However, S1P can also 
act intracellularly by regulating proapoptotic effector molecules 
such as BAK and BAX (35), TRAF2 (36), HDAC activity, and thus, 
epigenetic programs in the nucleus (37). The pathogenesis of dis-
ease within the target organs could result from both an excess of 
intracellular S1P and an imbalance of other sphingoid bases, but 
also from S1P signaling through the S1PRs. Podocytes are known 
to exhibit S1PRs, and as components of the glomerular filtration 
barrier, they could exhibit increased sensitivity to circulating S1P 
levels, especially under conditions of reduced SGPL1 activity, as 
has been shown in neuron primary cultures (38). In Drosophila, 
the phenotype we observed in nephrocytes upon constitutive Sply 
deletion is most likely to be secondary to intracellular accumula-
tion of S1P, but also to increased interstitial S1P levels, and cannot 
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LCB3 cloned into YCplac33), RH431, and MATα ura3 leu2 his4 bar1 
(49). pRS415-ADH2 was used to overexpress human SGPL1 in yeast. 
pRS415-ADH-SGPL1 was constructed by cloning SGPL1 in the XmaI-
XhoI sites of pRS415-ADH.
PHS toxicity test. Yeast dpl1Δ cells transformed with PRS415-ADH 
bearing WT or mutant human SGPL1 coding sequences were cultured 
overnight in synthetic defined minus leucine medium and spotted 
onto synthetic defined plates containing ethanol (vehicle control) and 
PHS (40 μM) as previously described (50).
Synthetic lethality test. RH4863 yeast cells were transformed 
with plasmids overexpressing human SGPL1 (WT and mutant vari-
ants) or yeast (positive control). Cells grown in synthetic defined 
minus leucine medium were 10-fold serially diluted and spotted 
onto synthetic defined–agar without leucine, without uracil, or with 
1 mg/ml 5-FOA (50).
Fly strains and generation of transgenic flies. Stocks were maintained 
on standard cornmeal-yeast food at 25°C. The following fly stocks 
were used: Sply05091/CyO,Act-GFP (from BL #11393), Df(2R)BSC433/ 
CyO,Act-GFP (from BL #24937), and Df(2R)247/CyO,Act-GFP (BL 
#7155), obtained from the Bloomington Stock Center, and Kirre RNAi 
(GD #14476), obtained from the Vienna Drosophila RNAi Center. Pros-
GAL4 (a gift from Barry Denholm, Center for Integrative Physiology, 
University of Edinburgh, Edinburgh, United Kingdom) y,w1118 was used 
as a WT control. Due to inbreeding, homozygous Sply05091 (Sply null 
allele) were almost impossible to obtain. We therefore generated Sply 
null hemizygous flies by crossing the Sply05091/CyO,Act-GFP flies with 
Df(2R)BSC433/ CyO,Act-GFP flies that carry a deletion of the Sply locus 
and 5 other contiguous genes. In the F1 generation, Sply null hemizy-
gous flies were identified by the absence of the balancer chromosome 
(CyO,Act-GFP). We confirmed the absence of Sply mRNA in Sply null 
hemizygous flies by reverse-transcriptase PCR (RT-PCR) (Supplemen-
tal Figure 15). For Sply rescue constructs, the HA tag (in-frame before 
the stop codon) and the corresponding SGPL1 human mutations were 
individually inserted by site-directed mutagenesis in the cloned 4-kb 
Sply genomic locus, including regulating sequences (–491 bp) and 3′ 
UTR (+1066 bp). Subsequently, the WT and mutant Sply rescue con-
structs were cloned into a pattB vector (Konrad Basler, Institute of 
Molecular Life Sciences, University of Zurich, Zurich, Switzerland) and 
injected into flies with an attP landing site at 76A2 by BestGene Inc. 
Primer sequences and cloning details are available in Supplemental 
Table 2. For the rescue experiments, 1 copy of the Sply rescue constructs 
was transferred by mating to the Sply null hemizygous background.
Viability assay. Fly crosses were allowed to lay eggs for 48 hours 
on standard cornmeal-yeast food. The percentage of hatching adults 
of the appropriate genotype was recorded. As a control, we crossed 
the Df(2R)BSC433/CyO,Act-GFP with Df(2R)247/CyO,Act-GFP (car-
rying a deletion nonoverlapping with Df[2R]BSC433), and the per-
centage of the normally viable Df(2R)BSC433/Df(2R)247 flies was 
recorded. On average, a total of 120 F1 hatching flies were counted per 
condition, and the experiments were repeated 6 times. Values report-
ed were normalized to the control.
Mice. Sgpl1–/– mice were previously described (11). Sgpl1–/– mice, 
littermate controls, and heterozygote breeders were handled in 
pathogen-free conditions.
TEM. After dissection, third instar garland nephrocytes and kid-
neys from Sgpl1+/+ and Sgpl1–/– mice were fixed in 2.5% glutaraldehyde 
at room temperature and processed for TEM with standard techniques.
aration, the effects of mutations were computationally assessed using 
the Residue Scanning module in BioLuminate 1.8 (Biologics Suite 
2015-1: BioLuminate, version 1.8).
Cell culture and transfection. Human podocytes were provided by M. 
Saleem (University of Bristol, Bristol, United Kingdom) and maintained 
at the permissive temperature of 33°C in RPMI + GlutaMAX-I (Gibco, 
Thermo Fisher Scientific) supplemented with 10% FBS, penicillin (50 
IU/ml)/streptomycin (50 μg/ml), and insulin–transferrin–selenium-X. 
RMCs (ATCC CRL-2573) were maintained in DMEM supplemented 
with 15% FBS, 0.4 mg/ml G418, and penicillin/streptomycin. SGPL1-
specific and control scrambled siRNAs were purchased from Dhar-
macon. siRNAs were transfected into podocytes or RMCs using Lipo-
fectamine RNAiMAX (Invitrogen). The target sequences of siRNAs 
are in Supplemental Table 1. Human fibroblasts were grown in DMEM 
supplemented with 15% FBS, penicillin/streptomycin, and nonessential 
amino acids (Invitrogen). HEK239T cells were used for lentivirus pro-
duction and transfected by the calcium phosphate precipitation method.
Immunoblotting, immunofluorescence, and GST pulldown assay. 
Experiments were performed as described previously (47). GST-
PAK1 and GST-Rhotekin beads were purchased from Cytoskeleton 
Inc. Anti-SGPL1 (AF5535, R&D Systems), anti-BiP (ab21685), anti– 
β-actin (ab6276, Abcam), anti-CD31 (MA3100, Thermo), anti-RAC1 
(610650), anti-CDC42 (610928), anti-GM130 (610822, BD Transduc-
tion Laboratories), anti-Myc (sc-789), anti-RHOA (sc-418), anti-WT1 
(sc-7385, Santa Cruz Biotechnology Inc.), anti-GOLGB1(HPA011008), 
anti–α-smooth muscle actin (A2547), anti-FLAG (F3165, Sigma-
Aldrich), anti-HA (11867423001, Roche), and anti-synaptopodin (20-
4694, American Research Products) antibodies were purchased from 
commercial sources. Immunoblotting was quantified by densitometry 
using ImageJ software (NIH). For immunofluorescence in Drosophila 
nephrocytes, third instar garland nephrocytes were dissected and 
fixed for 20 minutes in 4% paraformaldehyde at room temperature. 
For Kirre stainings, an alternative fixation method was used: nephro-
cytes were heat fixed during 5 seconds at 90°C in 0.7% NaCl, 0.05% 
Triton X-100 solution (48). The following primary antibodies were 
used: anti-Kirre (gift from Karl Fischbach, University of Freiburg) 
anti-HA, and Alexa Fluor 488 or Cyanine Cy3–conjugated anti–horse-
radish peroxidase (Jackson Immunoresearch). Nile red and Bodipy 
493/503 (Thermo Fisher Scientific) were used to stain lipid droplets. 
For albumin uptake assay, garland nephrocytes were dissected from 
third instar larvae in Schneider’s medium (Pan-Biotech), incubated 
for 2.5 minutes with 0.1 mg/ml Alexa Fluor 488–conjugated albumin 
(Thermo Fisher Scientific) at room temperature, and fixed in 4% PFA 
for 20 minutes. Confocal images were obtained with a Leica TCS SP8 
SMD, and ImageJ (NIH) was used for image analysis.
Migration and proliferation assay. Migration assays were performed 
using the xCELLigence system (ACEA Biosciences). For migration 
assays, 48 hours after transfection, 4 × 104 cells were plated with serum-
free media in the upper chamber of CIM-plate 16. The lower cham-
bers were filled with 10% FBS for chemoattraction or with serum-free 
media. For proliferation assays, 4 × 104 cells were plated in the E-plate 
16. The data obtained were analyzed with RTCA software (ACEA Bio-
sciences Inc.). Results are presented as the time versus cell index curve.
Yeast strains and plasmids. The following yeast strains were used 
in this study: BY4741-Euroscarf, MATa, his3Δ1, leu2Δ0, met15Δ0, 
ura3Δ0, dpl1Δ::KanMx, RH4863, MATα lcb3Δ::KanMx dpl1Δ::KanMx 
ura3 leu2 his4 ade2 bar1, pLCB3::URA3 (PCR amplified genomic 
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cells. JDS, BO, HYG, and WIC analyzed the Sgpl1–/– mouse model, 
critically evaluated mouse data, and wrote mouse studies. SG, N 
Lachaussée, MS, JP, and C Antignac performed Drosophila studies. 
AS performed TEM. JHS performed all LC/MS assays for quanti-
fication of cellular SPLY activity and SPL distribution. HR and VG 
performed yeast complementation experiments. SL, HYG, SG, 
MZ, VC, C Antignac, D Schapiro, MF, DAB, FS, NK, JG, TG, KS, 
VC, D Schanze, IF, YS, AST, BA, JD, RB, YP, EA, N Lloberas, AM, 
CES, FPB, JPM, VRD, AMC, MCW, MAC, NW, and FH recruited 
patients and gathered detailed clinical information for the study. 
JG and TG performed the immunophenotyping of patient EB-1. 
HS, RW, and GC performed structural molecular modeling of the 
SGPL1 enzyme. JDS directed studies undertaken by BO and JHS. 
All authors critically reviewed the paper. FH and C Antignac con-
ceived of and directed the entire project and wrote the paper with 
help from SL, SG, HYG, BO, and JDS.
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Sphingoid bases analysis. Sphingolipid metabolites from fly lar-
vae and patient fibroblast samples were extracted using a protocol 
described previously (51). Analytical systems used were composed of 
Agilent 1290 UPLC coupled with Agilent 6490 triple quadruple mass 
spectrometer. Analysis was carried out using multiple reaction moni-
toring (MRM) mode. The general source settings in the positive ion-
ization modes were as follows: gas temperature, 200°C; gas flow, 16 
minute–1; nebulizer, 20 psi; sheath gas temperature, 250°C; sheath gas 
flow, 11 minute–1; and capillary voltage, 3.0 kV. Specific MRM transi-
tions for fly sphingoid bases were programmed based on the transitions 
described previously (52). Chromatographic separation of sphingolip-
ids was performed with a Zorbax RRHD Eclipse Plus C18 (2.1 × 150 
mm, 1.8 μm) equilibrated at 50°C. A binary gradient of mobile phase 
A (water containing 0.2% formic acid and 2 mM ammonium formate) 
and B (methanol containing 0.2% formic acid and 1 mM ammonium 
formate) was delivered at a constant flow rate of 1 ml/min. The total 
run time was 10 minutes. Initial gradient was 70% B and increased 
to 100% B at 8 minutes and returned to baseline at 8.5 minutes and 
maintained until 10 minutes. Data processing of all metabolites was 
performed using MassHunter software (Agilent).
RT-PCR and real-time PCR. Total RNA was isolated from fibro-
blasts using a QIAGEN RNA extraction kit (QIAGEN). cDNA was pre-
pared using reverse transcriptase Superscript II (Invitrogen). PCR was 
performed using ReadyMix Taq PCR (Sigma-Aldrich) and the following 
primers: SGPL1 exon 4 forward, 5′-CTCACCAGGAAGATGCCCAT-3′ 
and SGPL1 exon 8 reverse, 5′-GCTTTGCAGGCCATCAGTAT-3′. The 
amplified PCR products were then cloned into a pGEM–T Easy Vector 
(Promega) and analyzed by Sanger sequencing. In Drosophila, relative 
expression levels were determined using the Absolute SYBR Green 
ROX Mix (ABgene) and specific primers as follows: Sply forward, 
5′-CTGGCTCTGGACTGTGATCTG-3′ and reverse, 5′-GACGCTT-
GCCACGAATGTAA-3′. Expression levels were normalized to actin.
Statistics. Results are presented as mean ± SEM or SD for the indi-
cated number of experiments. Statistical analysis of continuous data 
was performed with 2-tailed Student’s t test or 1-way ANOVA, with 
Dunnet’s, Bonferroni’s, or Dunn’s post hoc test, as appropriate. P < 
0.05 was considered statistically significant.
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